Comparative Pharmacology
Head-to-head clinical analysis: BUTORPHANOL TARTRATE PRESERVATIVE FREE versus PROPOXYPHENE HYDROCHLORIDE 65.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BUTORPHANOL TARTRATE PRESERVATIVE FREE versus PROPOXYPHENE HYDROCHLORIDE 65.
BUTORPHANOL TARTRATE PRESERVATIVE FREE vs PROPOXYPHENE HYDROCHLORIDE 65
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Butorphanol is a mixed agonist-antagonist opioid analgesic acting at mu- and kappa-opioid receptors; it exerts its analgesic effects primarily via kappa-opioid receptor agonism and partial mu-opioid receptor agonism/antagonism.
Propoxyphene is a centrally acting opioid agonist that binds to mu-opioid receptors in the central nervous system, inhibiting pain signal transmission and altering pain perception. It also has local anesthetic effects.
Adults: 1-2 mg intramuscularly or intravenously every 3-4 hours as needed for pain; alternatively, 0.5-1 mg intravenously every 3-4 hours. For epidural administration: 1-2 mg at the lumbar level, may repeat once after 60 minutes if needed.
65 mg orally every 4 hours as needed for pain; maximum 390 mg/day.
None Documented
None Documented
Terminal elimination half-life: 2.5-3.5 hours (IV); 4-6 hours (IM). In hepatic impairment, half-life may increase to 5-9 hours; in renal impairment, minimal change unless severe.
6-12 hours (mean ~8 hours); prolonged in hepatic impairment and elderly; accumulation possible with repeated dosing.
Primarily renal (70-80% as unchanged drug and metabolites; 5% unchanged), biliary/fecal (15-20%), with enterohepatic recirculation.
Renal excretion of unchanged drug (approximately 20-30%) and metabolites; approximately 40-60% as conjugated metabolites; minor biliary/fecal elimination.
Category C
Category C
Opioid Analgesic
Opioid Analgesic